Fragile X Syndrome Forecast in 11 Major Markets 2016-2026: Focus on USA, France, Germany, Italy, Spain, UK, Australia, Japan, Brazil, India and China

Dublin, Dec. 22, 2016 -- Research and Markets has announced the addition of the "Fragile X Syndrome Forecast in 11 Major Markets 2016-2026" report to their offering.

Fragile X syndrome (FXS) is an X-linked dominant genetic disorder. It is caused by a defect in the fragile-X mental retardation 1 gene (FRM1); this defect prevents the FRM1 gene from expressing FMRP. The FMRP protein, most commonly found in the brain, is essential for normal cognitive development and female reproductive function. FXS is the leading genetically inherited cause of intellectual and developmental disability.

This report provides the current prevalent population for Fragile X Syndrome across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Australia, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Fragile-X have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Features associated with Fragile X Syndrome include:

- Autistic-like features
- Fragile X tremor ataxia syndrome (FXTAS)
- Fragile X primary ovarian insufficiency (FXPOI)
- Attention problems
- Anxiety
- Hyperactivity

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Co-morbid Conditions/Features Associated with the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Fragile X Syndrome

10. Features of Fragile X Syndrome Patients

11. Abbreviations used in the Report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/bbgxfm/fragile_x

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Central Nervous System Drugs